December 4, 2017
Qvella Raises US$20M in Series B Financing to Fund Clinical Trials, On-going Research, Team Expansion, and Manufacturing Buildup
December 4, 2017 — TORONTO — Qvella, a leading molecular diagnostics company, today announced it has closed US$20 million in Series B financing. The funding round was co-led by Qvella’s existing investor syndicate—including RA Capital, Whitecap Venture Partners, Hatteras Ventures, and Sands Capital—and new strategic investor bioMérieux, a world leader in the field of in vitro diagnostics.
November 28, 2017
G1 Therapeutics and AstraZeneca Enter Clinical Trial Collaboration in Non-Small Cell Lung Cancer
Nov. 28, 2017 (GLOBE NEWSWIRE) — RESEARCH TRIANGLE PARK, N.C. — G1 Therapeutics, Inc. (NASDAQ:GTHX), a clinical-stage oncology company, today announced a clinical trial collaboration with AstraZeneca to evaluate AstraZeneca’s epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Tagrisso® (osimertinib) in combination with G1’s oral CDK4/6 inhibitor G1T38 for the treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC).
October 31, 2017
Ribometrix Raises $7.5 Million in Seed Funding to Advance Platform for Discovering and Developing Small Molecule Modulators of RNA to Treat Human Diseases
Oct. 31, 2017 (MARKETWIRED) — DURHAM, NC — Ribometrix, Inc., a biotech company dedicated to discovering and developing small molecule modulators of RNA to treat disease, has raised $7.5 million in seed capital.
September 19, 2017
Sir Andrew Witty Joins Hatteras Venture Partners
Sept. 19, 2017 — DURHAM, NC — Hatteras Venture Partners today announced it has named Sir Andrew Witty a Venture Partner. Mr. Witty will primarily focus on the strategic positioning of Hatteras and its portfolio companies in the ever-changing global health care industry. In addition, Mr. Witty will provide leadership counsel to Hatteras’ portfolio companies.
September 18, 2017
Rodin Therapeutics Advances Synaptic Resilience Strategy With $27 Million In Financing And Expands Board Of Directors
Sept. 18, 2017 — CAMBRIDGE, MA — Rodin Therapeutics, a biotechnology company discovering and developing novel therapeutics to boost synaptic resilience, announced today significant progress in advancing the company’s strategic vision, including the completion of a $27 million financing round, and the addition of three new members to its Board of Directors.
August 4, 2017
Veritas Genetics Acquires Curoverse to Deploy Large-Scale Artificial Intelligence and Machine Learning in Genomics
Aug. 3, 2017 (PRNEWSWIRE) — BOSTON — Veritas Genetics, the genome company, announces the acquisition of Boston-based Curoverse, the preeminent computing and bioinformatics company behind the Personal Genome Project (PGP) at Harvard Medical School, and creator of the open-source platform Arvados. Curoverse software is used by industry leaders such as the Wellcome Trust Sanger Institute to manage, process and share petabytes of genomic and biomedical data as well as facilitate AI and machine learning.
June 7, 2017
HistoSonics Technology’s Exciting Preclinical Results to be Presented at the World Conference on Interventional Oncology (WCIO) 2017
June 7, 2017 (PRNEWSWIRE) —ANN ARBOR, MI — HistoSonics, Inc., a venture-backed medical device company developing a new image-guided, robotically assisted, platform therapy that is non-invasive and non-thermal, announced two significant developments today.
May 30, 2017
G1 Therapeutics to Present Clinical Data on CDK4/6 Inhibitor Trilaciclib at the 2017 American Society of Clinical Oncology Annual Meeting
May 30, 2017 (GLOBE NEWSWIRE) — RESEARCH TRIANGLE PARK, N.C. — G1 Therapeutics, Inc. (NASDAQ:GTHX), a clinical-stage oncology company, today announced that Phase 1b data from the ongoing Phase 1b/2a study of its lead CDK4/6 inhibitor trilaciclib as a first-line combination treatment in patients with extensive stage small-cell lung cancer (SCLC) will be presented in a poster session at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held June 2 – 6 at McCormick Place in Chicago.
May 16, 2017
G1 Therapeutics Announces Pricing of Initial Public Offering
May 16, 2017 (GLOBE NEWSWIRE) — RESEARCH TRIANGLE PARK, N.C. — G1 Therapeutics, Inc., a clinical-stage oncology company, today announced the pricing of its initial public offering of 7,000,000 shares of common stock at a public offering price of $15.00 per share for aggregate gross proceeds of $105,000,000.
April 18, 2017
NeuroTronik Announces $23.1 Million Series B Preferred Stock Financing
April 18, 2017 — DUBLIN IRELAND AND DURHAM, N.C., USA — NeuroTronik Limited and NeuroTronik, Inc. today announced closing on a $23.1 million Series B Preferred Stock Financing, tranched in line with project plan milestones. The funding was led by Boston Scientific Group, plc. Other major investors include Hatteras Venture Partners, Synergy Life Science Partners, Lord Baltimore Investment Partners, Mountain Group Capital, and Sovereign’s Capital. The investor group also includes other financial and industry participants.